Results 11 to 20 of about 1,931,799 (309)

Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case–control study and meta-analysis

open access: yesPLoS Medicine, 2023
Background Current or recent use of combined oral contraceptives (containing oestrogen+progestagen) has been associated with a small increase in breast cancer risk.
Danielle J Fitzpatrick   +4 more
semanticscholar   +1 more source

Injectable and oral contraceptive use and cancers of the breast, cervix, ovary, and endometrium in black South African women: case-control study. [PDF]

open access: yesPLoS Medicine, 2012
Oral contraceptives are known to influence the risk of cancers of the female reproductive system. Evidence regarding the relationship between injectable contraceptives and these cancers is limited, especially in black South Africans, among whom ...
Margaret Urban   +6 more
doaj   +1 more source

The gingival condition of oral contraceptives users at desa Hegarmanah, Kecamatan Jatinangor

open access: yesPadjadjaran Journal of Dentistry, 2010
The change of hormonal condition is a systemic condition that affected the periodontium condition. Oral contraceptives is one of the systemic risk that can change hormonal condition.
Miduk Sibuea   +2 more
doaj   +1 more source

Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women.

open access: yesJAMA psychiatry, 2019
Importance Oral contraceptives have been associated with an increased risk of subsequent clinical depression in adolescents. However, the association of oral contraceptive use with concurrent depressive symptoms remains unclear.
Anouk E. de Wit   +5 more
semanticscholar   +1 more source

Estimate of venous thromboembolism and related-deaths attributable to the use of combined oral contraceptives in France. [PDF]

open access: yesPLoS ONE, 2014
PURPOSE: To estimate the number of venous thromboembolic events and related-premature mortality (including immediate in-hospital lethality) attributable to the use of combined oral contraceptives in women aged 15 to 49 years-old between 2000 and 2011 in ...
Aurore Tricotel   +3 more
doaj   +1 more source

Role of CYP3A in Oral Contraceptives Clearance

open access: yesClinical and Translational Science, 2018
We evaluated the relative contribution of CYP3A in the overall clearance of commonly used combined oral contraceptives (COCs) based on the results of clinical DDI studies in the literature and new drug applications (NDAs).
N. Zhang   +8 more
semanticscholar   +1 more source

No evidence that women using oral contraceptives have weaker preferences for masculine characteristics in men's faces.

open access: yesPLoS ONE, 2019
Previous research has suggested that women using oral contraceptives show weaker preferences for masculine men than do women not using oral contraceptives.
Urszula M Marcinkowska   +4 more
doaj   +1 more source

Out-of-pocket spending for oral contraceptives among women with private insurance coverage after the Affordable Care Act

open access: yesContraception: X, 2020
Objectives: We aimed to identify which types and brands of oral contraceptive pills have the largest shares of oral contraceptive users in large employer plans with out-of-pocket spending and which oral contraceptives have the highest average annual out ...
Brittni Frederiksen   +2 more
doaj   +1 more source

Evidence for Stress-like Alterations in the HPA-Axis in Women Taking Oral Contraceptives

open access: yesScientific Reports, 2017
Using oral contraceptives has been implicated in the aetiology of stress-related disorders like depression. Here, we followed the hypothesis that oral contraceptives deregulate the HPA-axis by elevating circulating cortisol levels. We report for a sample
Johannes Hertel   +19 more
semanticscholar   +1 more source

Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three‐arm randomized controlled trial

open access: yesDepression and Anxiety, 2017
Although traditionally dosed combined oral contraceptives (COCs) (21 days of active pills, 7 days of inactive pills) have not been demonstrated as superior to placebo for the treatment of premenstrual dysphoria (PMD), some randomized controlled trials ...
T. Eisenlohr-Moul   +4 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy